The global threat of drug-resistant infections is escalating, leaving sub-Saharan African populations exposed to life-threatening illnesses. The 2026 Antimicrobial Resistance (AMR) Benchmark report reveals a dire situation across 17 sub-Saharan African countries, where none of the assessed companies have registered child-friendly versions of their existing antimicrobial products.
This access gap severely limits treatment options for children, fueling resistance and putting vulnerable populations at risk. In Uganda alone, AMR-related deaths surpassed HIV and tuberculosis combined in 2021, with children under 5 accounting for nearly half of these fatalities.
The report highlights a shrinking pipeline for new treatments, with major companies like Johnson & Johnson ceasing their infectious disease R&D. Only a few large research-based companies continue to invest in antimicrobial R&D, leaving the deficit severe for pediatric medicine.
However, there are glimmers of hope. Small- and medium-sized enterprises (SMEs) identified seven innovative medicine projects targeting deadly drug-resistant pathogens. Five companies are actively working to bridge the access gap by registering their pediatric formulations in low- and middle-income countries.
The 2026 AMR Benchmark stresses that overcoming this crisis requires industry-wide action, including comprehensive approaches for R&D, manufacturing, access, and stewardship. The report emphasizes the need for intensified efforts to address the growing global threat of drug-resistant infections.
Source: https://pmldaily.com/news/2026/03/big-pharma-pulls-back-from-superbug-research-as-global-threat-accelerates.html